Gliomedin, which has been implicated as a major player in genesis of the nodes of Ranvier, contains two collagenous domains and an olfactomedin-like domain and belongs to the group of type II transmembrane collagens that includes collagens XIII and XVII and ectodysplasin A. One characteristic of this protein family is that constituent proteins can exist in both transmembrane and soluble forms. Recently, gliomedin expressed at the tips of Schwann cell microvilli was found to bind axonal adhesion molecules neurofascin and NrCAM in interactions essential for Na ؉ -channel clustering at the nodes of Ranvier in myelinating peripheral nerves. Interestingly, exogenously added olfactomedin domain was found to have the same effect as intact gliomedin. Here we analyze the tissue form of gliomedin and demonstrate that the molecule not only exists as full-length gliomedin but also as a soluble form shed from the cell surface in a furin-dependent manner. In addition, gliomedin can be further proteolytically processed by bone morphogenetic protein 1/Tolloid-like enzymes, resulting in release of the olfactomedin domain from the collagen domains. Interestingly, the later cleavage induces formation of higher order, insoluble molecular aggregates that may play important roles in Na ؉ -channel clustering.
Collagens and other proteins with collagenous domains constitute the most abundant components of the extracellular matrix. They also play essential roles in development and provision of structural integrity to most tissues and organs and can be divided into nine subgroups (1) . Type II-oriented transmembrane collagens are one such subgroup. These play roles in cellmatrix interactions both as integral membrane proteins and as shed forms cleaved from cell surfaces by limited proteolysis (2) . Transmembrane collagens XIII (3) and XXV (4) and transmembrane protein ectodysplasin A, which is not formally a collagen but which contains collagenous domains (5) , are shed by cleavage at the juxtamembrane consensus sequence (K/R)X n (K/R) (n ϭ 0, 2, 4, 6). Such cleavage is by furin-like proprotein convertases of the S8 family of Kex/subtilisin-related serine endopeptidases (6 -8) . In contrast, collagen XVII is not directly cleaved by furin-like convertases. Rather, furin-like convertases activate ADAM (a disintegrin and metalloproteinase) family proteinases that cleave collagen XVII (2, 9) .
The designation colmedin (collagen repeat plus olfactomedin domain) describes a new type of transmembrane collagen (10) containing an ϳ260-amino acid olfactomedin-like domain at the C terminus. The prototype, olfactomedin, was first identified in the extracellular mucus matrix of the olfactory neuroepithelium of Rana catesbeiana (11, 12) . With the exception of the sea urchin protein amassin (13) , all subsequently characterized olfactomedin-like domain-containing proteins are expressed in neural tissues and seem involved in neural function. Noelin-1 participates in generation of neural crest cells (14, 15) , photomedins are expressed in retina (16) , tiarin is responsible for neural tube dorsalization (17) , CIRL/latrophilin acts as a receptor involved in exocytosis of synaptic vesicles (18) , and myocilin, expressed in ciliated epithelium of photoreceptors, is linked to the pathogenesis of open angle glaucoma (19 -21) . Optimedin, found in brain and eye, interacts with myocilin via its olfactomedin domains (22) , providing evidence of a strong adhesive function for such domains. The molecular mechanism by which olfactomedin domains carry out adhesive functions remains unknown.
The colmedin gliomedin has been identified in all sequenced vertebrate genomes. In invertebrates several orthologous genes have been identified, with one copy of the gene found in Drosophila melanogaster and two copies, unc-122 (uncoordinated movement) and Cof-2 (colmedin family member 2), identified in Caenorhabditis elegans. Duplication like the latter has not been detected in other species. Of all collagen types, essentially only collagens IV and XVIII are conserved throughout the animal kingdom (1) . Thus, conservation of gliomedin-like genes in such a broad range of species suggests functions fundamental to life. In C. elegans, protein UNC-122 is located at neuromuscular junctions (NMJ) 2 and is proposed to be involved in maintaining a structural microenvironment that allows efficient NMJ signaling (10) . In contrast, gliomedin is reportedly a glial ligand for axonal adhesion molecules neurofascin and NrCam at the nodes of Ranvier in the peripheral nervous system (23) . Myelinated axons allow saltatory conduction at the nodes of Ranvier, which are periodic interruptions in the myelin sheath that are characterized by clustering of voltage-gated Na ϩ channels (24) . Development of the nodes is not intrinsically regulated by axons but instead requires close contact with Schwann cell processes for Na ϩ channel clustering (25) . Gliomedin, expressed on the tips of Schwann cell microvilli flanking the nodes, appears to interact with axonal receptors NrCAM and neurofascin in an early step necessary to the clustering of Na ϩ channels and associated scaffolding molecules that define node formation (23) .
The bone morphogenetic protein 1 (BMP-1)/Tolloid-related metalloproteinases play key roles in morphogenetic events by regulating formation of mammalian extracellular matrix via biosynthetic processing of precursor proteins into mature, functional matrix components. These include collagens I-III, V, VII, and XI; the collagen cross-linking enzyme lysyl oxidase, basement membrane component laminin 332, and proteoglycans biglycan, osteoglycin, and perlecan (26 -30) . BMP-1/ Tolloid-related proteinases also affect morphogenesis by activating a subset of the transforming growth factor-␤ superfamily of growth factors, including BMP-2 and -4 and growth and differentiation factors 8 and 11 (30) . In fact, BMP-1/Tolloidrelated proteinases may serve to orchestrate extracellular matrix formation and signaling by such molecules in morphogenesis and homeostasis.
Here we describe shedding and processing of the Schwann cell transmembrane protein gliomedin. Our results demonstrate that shedding of the ectodomain is accomplished by proteases of the furin family using the juxtamembrane RNKR cleavage site. Additional processing of gliomedin is dependent on BMP-1/Tolloid-related proteinases and occurs in the linker region between collagenous and olfactomedin domains. The latter processing gives rise to free olfactomedin domains, which initiate formation of high order insoluble molecular aggregates.
EXPERIMENTAL PROCEDURES
cDNA Isolation-In a search for novel transmembrane collagens, a novel expressed sequence tag (dbEST) was identified (GenBank TM accession number NM_177350) that showed homology to the UNC-122 protein (uncoordinated movement) in C. elegans (10) . Prediction programs used for the primary structure analysis of gliomedin were TMHMM Server Version 2.0, Coils Version 2.1, NetNGlyc Version 1.0, NetOGlyc Version 3.1, and Pfam Version 19.0. Sequences used for comparison were the following: CG6867 (D. melanogaster) AAF48788; gliomedin (murine) NP_796324; olfactomedin (murine) AAH26547.1; colmedin family member 2 (C. elegans) AAN60526.2; unc-122 (C. elegans) NP_493598.1; collagen XIII (murine) NP_031757.
Recombinant Expression of Secreted Gliomedin and Its Fragments-The following fragments of gliomedin were amplified and cloned into an episomal expression vector: the olfactomedin domain (nucleotides 814 -1686, NM_177350), the ectodomain (nucleotides 147-1686, NM_177350), and the fulllength molecule (nucleotides 21-1686, NM_177350). One g of total RNA from murine skeletal muscle, retina, and brain was reverse-transcribed, and PCR was performed following the manufacturer's instructions (Expand Long Template PCR System, Roche Diagnostics). For the olfactomedin domain construct, NheI and BglII sites were introduced using primers aacgctagcacggccaccaaacgtgttcaacag (fw) and gtgagatctccgctgacttgatgccgctgac (rev), respectively. To clone the ectodomain, NheI (fw, cacgctagcagtgctgtgccagtggcggggg) and BglII (rev, gtgagatctccgctgacttgatgccgctgac) sites were introduced. For cloning the gliomedin full-length construct, KpnI and BglII sites were inserted using primers fw (aacggtaccccggcctgagcacgcagacatg) and rev (gtgagatctccgctgacttgatgccgctgac). PCR products were purified on an agarose gel (Qiagen) and subcloned (rapid DNA ligation kit, Roche Diagnostics) into a PCEP-4 expression vector (modified by M. Koch) that contains 3Ј His 8 and FLAG tags. Site-directed mutagenesis of full-length gliomedin was carried out using the QuikChange II site-directed mutagenesis kit (Stratagene) to introduce R91A91 (fw, gcagcggccaacaagcgcagccacaacggc; rev, cttgttggccgctgcgctcatggggtcctg) and D278A/ D279A mutations (fw, cccaatgctgctaccttggtgggaagagctgat; rev, caaggtagcagcattgggtatgacacacgtctc). Ligated vectors were transformed into TOP 10 bacterial cells (Invitrogen), and the clones were verified by sequencing (ABI Prism 377 DNA Sequencer, Applied Biosystems, ZBA CMM Cologne). HEK-293 cells (Invitrogen) cultured in Dulbecco's modified eagle medium (DMEM) F-12 (Invitrogen) were transfected (FuGENE, Roche Diagnostics or Lipofectamin-2000, Invitrogen) with the expression vector and selected with puromycin (Sigma) after 2 days. Stably transformed HEK-293 cells were pseudo-subcloned, and the clones with the highest protein production were expanded for large scale production. Other cell lines used were Cos-7 (ATCC CRL 1651) and RN-2 (schwannoma cell line, a kind gift from Prof. Stoffel) cultured in DMEM-F-12 (Invitrogen) and C6 (ATCC CCL 107, a kind gift from Prof. Stoffel) cultured in Ham's F-10 medium.
Purification of Recombinant Fragments-Three liters of serum-free supernatant from these cells were collected and supplemented with 50 M phenylmethylsulfonyl fluoride (Fluka). The supernatant was titrated with 0.5 M NaH 2 PO 4 buffer to a final pH of 7.6 and applied to a cobalt-charged Talon Superflow column (Takara, Clontech) or nickel-charged nickelSepharose 6 Fast Flow column (GE Healthcare). The column was washed with 10 mM Tris and 150 mM NaCl at pH 8, and elution was carried out with 20 mM Tris and 300 mM NaCl at pH 7.8 and increasing imidazole concentrations (5-80 mM). In some cases the His tag was digested with thrombin (isolated from bovine plasma, Sigma) according to the protocol from EMD Bioscience, and protein was again applied to a cobaltcharged Sepharose column.
Antibody Production-The purified olfactomedin domain of murine gliomedin was injected into a rabbit (KR 34) and a guinea pig (KG 44) for polyclonal antibody production. The resulting KR 34 and KG 44 antisera were affinity-purified on a murine gliomedin protein column that was prepared by coupling the olfactomedin domain to CNBr-activated Sepharose 4B (GE Healthcare). Bound antibodies were eluted with triethylamine at pH 11.5 and immediately neutralized.
N-Glycosidase F Digestion-To remove all N-linked glycans of the highly glycosylated gliomedin protein, an N-glycosidase F digestion was performed. 3-5 g of protein of the different purified gliomedin fragments were diluted in Tris-buffered saline, pH 7.4, containing 1% SDS, heated for 15 min at 95°C, and diluted again to achieve a final concentration of 0.1% SDS and 0.5% Nonidet P-40. 3 units of N-glycosidase F (Roche Diagnostics) were added and incubated overnight at 37°C. Digested fragments were analyzed on a 10% acrylamide SDS-PAGE gel followed by staining with Coomassie Brilliant Blue G250.
Rotary Shadowing-Solutions of single proteins were diluted to 10 g/ml with 0.2 M ammonium bicarbonate, and after the addition of an equal volume of glycerol, the solutions were sprayed onto freshly cleaved mica sheets. The samples were immediately placed on the holder of a MED 010 evaporator (Balzers S.p.A., Milan, Italy), and rotary shadowing was carried out as previously described (31) .
Immunodetection of Gliomedin-KR 34 and KG 44 pAbs were used for immunofluorescence staining of mouse sciatic nerve as described previously (32) . The dissected sciatic nerves of 3-10-week-old mice were incubated in collagenase (3.5 mg/ml, Sigma-Aldrich) and dispase II (2.4 units/ml, Roche Diagnostics, Germany) for up to 30 min at 37°C. Nerves were then rinsed with 50 mM PBS, pH 7.4, and placed on coverslips previously coated with collagen solution type I from calf skin (Sigma-Aldrich) diluted 1:10 in PBS. Nerve fibers were gently separated with fine needles to achieve single fibers followed by fixation in 4% paraformaldehyde. Nerves were rinsed again with 50 mM PBS, pH 7.4, and dried for 5 min at 37°C. Samples were blocked for 1.5 h using 0.3% Triton X-100 and 10% fetal calf serum in 100 mM PBS, pH 7.4, at room temperature. Incubation with primary antibodies pAb KR 34 (1:1000 in blocking solution), pAb KG 44 (1:1000), rat anti-laminin ␥1 chain monoclonal antibody (Chemicon International, Temecula, CA; 1:2000), or anti-Na ϩ channel (III-IV linker region rabbit affinity-purified IgG, Upstate Biotechnology, Lake Placid, NY; 1:100) was done overnight at 4°C or 3 h at room temperature. A 1-h incubation was followed with Cy3 goat anti-rabbit 1:400 (Jackson ImmunoResearch), Alexa 488 goat anti-rat 1:400 (Molecular Probes), or Cy3 goat anti-guinea pig 1:300 (Dianova, Germany) coupled secondary antibody at room temperature. Samples were rinsed again with PBS, pH 7.4, and mounted with fluorescent mounting medium (Dako Cytomation). Nerves were imaged with a confocal laser-scanning microscope (Leica TCS SL). Images shown here were created using Adobe Photoshop (Version 7.0). No enhancements other than contrast and brightness were performed on the images.
For immunoblotting, proteins were separated by SDS-PAGE under reducing or non-reducing conditions and transferred onto nitrocellulose (Schleicher & Schuell). Where indicated, 6 M urea was added to the SDS gel and sample buffer to avoid protein aggregation. 4 -20% pre cast gels (NuPAGE Bis-Tris Gels, Invitrogen) were used for improved separation. The affinitypurified antibody KR 34 was diluted 1:1000 -1:5000 in Trisbuffered saline containing 3% milk powder and 0.05% Tween 20 or PBS-Tween containing 5% milk. Incubation overnight (4°C) was followed by detection with horseradish peroxidase (HRP)-linked swine anti-rabbit antibody (1:4000) (Dako Cytomation) or goat anti-rabbit IgG-HRP (Bio-Rad) diluted 1:20,000 in PBSTween with 0.5% milk. The monoclonal mouse anti-His 6 antibody (Dianova, Germany) was diluted 1:1000 in Tris-buffered saline containing 3% bovine serum albumin and 0.05% Tween 20 and incubated overnight (4°C) followed by incubation with horseradish peroxidase-linked sheep anti-mouse secondary antibody for 1 h at room temperature. Signals were visualized with Western blotting detection reagents (GE Healthcare and Pierce). For densitometric measurements signals were recorded with a Diana III (camera) and quantified with an Aida image analyzer 3.27. Coomassie staining was performed with Coomassie Brilliant Blue G250.
Tissue and Cell Culture Extractions-For analysis of gliomedin in tissue, sciatic nerves of 2-month-old mice were dissected and extracted in buffer containing 6 M urea plus 2% Triton X-114 at 4°C followed by centrifugation at 14,000 ϫ g at 4°C for 30 min. For collagenase digestion, 40 l of supernatant was used, and immunoblotting was carried out with 30 l of supernatant. Extraction of cultured cell layers was performed for 30 min on ice using a neutral buffer containing 1% Nonidet-P40, 0.1 M NaCl, 25 mM Tris-HCl, pH 7.4, 2 mM EDTA, 1 mM Pefabloc (Roche Diagnostics) and other protease inhibitors (Complete mix, Roche Diagnostics). The cell lysate was then harvested with a cell scraper and centrifuged at 14,000 ϫ g for 30 min at 4°C. The supernatant was used for further analysis. To analyze proteins in culture media, 2 mM EDTA and 1 mM Pefabloc (Roche diagnostics) were added to the medium. Cell debris was removed by centrifugation at 500 ϫ g for 10 min at 4°C.
Collagenase Digestion-As part of analyzing the domain structure of gliomedin, tissue extracts were subjected to collagenase digestion. Incubation with 200 units/ml highly purified bacterial collagenase (Advanced Biofactures Inc., Lynbrook, NY) was carried out using 50 l of tissue extraction buffer containing 1 mM Pefabloc (Roche Diagnostics) and 10 mM CaCl 2 at pH 8. After incubation for 4 h at 37°C, the reaction was stopped by adding EDTA.
Cell Surface Biotinylation-Cells previously cultured in 0.25 mM ascorbate (Sigma) and ascorbate-phosphate (0.45 mM, Sigma) were washed 3 times with PBS and surface-biotinylated for 5 min with Biotin-X-NHS (Calbiochem) followed by extensive washing with PBS. Cells were then cultured in medium supplemented with ascorbate and ascorbate-phosphate, and both media and cell extracts were collected at different time points for up to 48 h. Protein concentrations were quantified using a BCA (bicinchoninic acid) protein assay kit (Pierce). Immunoprecipitation was performed with pAb KR 34 coupled to CNBr-Sepharose 4B (GE Healthcare), and precipitates were immunoblotted. Biotinylated gliomedin was detected with a streptavidin-biotinylated horseradish peroxidase complex (GE Healthcare).
Protease Inhibitor Studies-Stably transfected Cos-7 or HEK-293 cells were plated at subconfluence and incubated with media supplemented with ascorbate/ascorbate-phosphate and inhibitors of interest in different concentrations for a defined period of time. Cell extracts and media were handled as described above, and protein concentrations were quantified. Equal amounts of supernatant were precipitated with 4ϫ acetone at Ϫ20°C overnight and collected by centrifuging 15 min at 14,000 ϫ g at 4°C. The pellet was resuspended in 50 mM Tris-HCl, 65 mM NaCl, 5 mM EDTA, and 1 mM Pefabloc, pH 7.4. The following protease inhibitors were used: AEBSF (4-(2-aminoethyl)benzenesulfonyl fluoride; Merck), furin inhibitor decanoyl-Arg-Val-Lys-Arg-chloromethyl ketone (Calbiochem-Novabiochem), E-64 (L-3-carboxy-2, 3-trans-epoxypropionyl-leucylamido(4-guanidino)butane), pepstatin A (Sigma), aprotinin, 1,10-ortho-phenanthroline, BB-3103 and BB 3241 (both British Biotech), and IC-3 (Immunex Corp.).
For BMP-1/Tolloid inhibitor studies, stably transfected HEK-293 cells were cultured in complete medium consisting of DMEM supplemented with 10% fetal bovine serum (Hyclone), 1 mM L-glutamine, and 10 IU/ml penicillin/streptomycin. At 80% confluence, cells were incubated for 24 h in complete medium containing 100 g/ml soy bean trypsin inhibitor with/ without 20 M FG2575 (a kind gift of FibroGen, Inc.), a specific inhibitor of the BMP-1/Tolloid-like proteinases (33) . Cells were then rinsed in PBS, washed for 15 min in serum-free DMEM, and incubated an additional 24 h in serum-free DMEM with 100 g/ml soy bean trypsin inhibitor in the presence or absence of 20 M FG2575. Conditioned media were collected from cells and adjusted to 1 mM N-ethylmaleimide, 1 mM p-aminobenzoic acid, 0.5 mM phenylmethylsulfonyl fluoride, and 5 mM EDTA. Conditioned media were then precipitated in 75% ethanol at 4°C overnight. Precipitated proteins were recovered by centrifugation at 58,000 ϫ g for 45 min. Pellets were dried and resuspended in buffer containing 150 mM NaCl, 50 mM Tris-HCl, pH 7.5, and the protease inhibitors N-ethylmaleimide (1 mM), paminobenzoic acid (1 mM), phenylmethylsulfonyl fluoride (0.5 mM), and EDTA (5 mM).
N-terminal Sequencing of Gliomedin Fragments-Purified gliomedin fragments were subjected to electrophoresis using a 4 -20% SDS-polyacrylamide gel (Invitrogen) and transferred onto a polyvinylidene difluoride membrane (Immobilon P, Millipore), and proteins were visualized by 0.1% Coomassie Brilliant Blue G-250. Desired protein bands were excised and subjected to N-terminal amino acid sequencing using a 473A protein sequencer (Applied Biosystems, ZBA CMM Cologne).
In Vitro BMP-1 Cleavage Assay and N-terminal Amino Acid Analysis-150 ng of recombinant gliomedin ectodomain was incubated in the presence or absence of 40 ng BMP-1 at 37°C for 18 h in a total reaction volume of 20 l of 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM CaCl 2 , 0.01% Brij 35 (Sigma). Reactions included protease inhibitors N-ethylmaleimide (1 mM), p-aminobenzoic acid (1 mM), and phenylmethylsulfonyl fluoride (0.5 mM) to prevent nonspecific proteolysis. Reactions were stopped by the addition of 10ϫ SDS-PAGE sample buffer with 1% ␤-mercaptoethanol and boiling for 5 min. For amino acid analysis, 1.5 g of gliomedin ectodomain was incubated with 500 ng of BMP-1 for 18 h at 37°C. Samples were separated by SDS-PAGE on 10% acrylamide gels. Samples were electrotransferred to Sequi-blot polyvinylidene difluoride membranes (Bio-Rad), and proteins were visualized with 0.025% Coomassie Brilliant Blue G-250. Bands representing cleaved gliomedin and aggregated gliomedin were excised, and their N-terminal amino acid sequences were determined by automated Edman degradation at the Harvard University Microchemistry Facility using a PerkinElmer/Applied Biosystems Division Procise 494 HT Protein Sequencing System.
RESULTS
Because of the important roles that known transmembrane collagens have been shown to play in development and disease (2), we initiated investigation of a novel transmembrane protein with collagenous domains, which has since been designated gliomedin (23) . Gliomedin is predicted to be a 59-kDa type II transmembrane protein with an N-terminal intracellular stretch comprising 12 amino acids, a juxtamembrane coiledcoil region of 14 amino acids, and 2 collagenous repeats, representing 20% of the protein mass. A highly conserved olfactomedin domain comprising 245 amino acids constitutes the protein C terminus (Fig. 1A) . The amino acid sequence contains six cysteine residues for possible inter-and intradisulfide bonding as well as putative N-linked and O-linked glycosylation sites (Fig. 1A ). An orthologous gliomedin gene in C. elegans is termed unc-122 (uncoordinated movement) (Fig. 1B) . In vertebrates gliomedin is the only protein possessing both collagen and olfactomedin domains, whereas in C. elegans both unc-122 and a second gene product, Cof-2 (collagen/olfactomedin domain-containing protein 2), contains both features. The colmedin CG6867 identified in D. melanogaster also includes two IgG-like domains that are absent in the other orthologous genes. Shown for comparison, collagen XIII is like gliomedin in that both are type II transmembrane proteins with very small cytoplasmic domains (Fig. 1B) .
Biochemical Analysis of Gliomedin and Antibody ProductionImmunoblot analysis was performed on the media of HEK-293 cells stably expressing His-tagged recombinant gliomedin olfactomedin domain that included 41 amino acids of the linker region. Such analysis detected a band slightly larger than 50 kDa, suggesting considerable post-translational modification of a protein fragment predicted to have a mass of ϳ32 kDa ( Fig.  2A, lane 1) . Similarly, media of cells expressing the entire gliomedin ectodomain, starting with amino acid 37, contained a band corresponding to a molecular mass of ϳ90 kDa (Fig. 2A , lane 2) despite a predicted molecular mass of 56 kDa. Using the anti-His antibody, lesser amounts of gliomedin were detectable in the media of cells expressing full-length recombinant gliomedin ( Fig. 2A, lane 3) , presumably because of retention of considerable amounts of full-length protein on the cell surface. However, detection of some gliomedin in the media of these cells was consistent with shedding from the cell surface.
To prepare anti-gliomedin antibodies for additional studies, including studies of endogenous gliomedin, rabbits and guinea pigs were immunized with purified recombinant olfactomedin domain that included 41 amino acids of the linker region. Affinity-purified rabbit antibodies (KR 34) specifically recognized olfactomedin/linker and ectodomain fragments (Fig. 2B, lanes  1 and 2) and a band about the same size as the ϳ90-kDa ectodomain in the media of cells expressing recombinant full-length gliomedin (Fig. 2B, lane 3) . Because gliomedin contains a transmembrane domain at the N terminus, the full-length form should be retained in the plasma membrane. Thus, detection of the ϳ90-kDa form in lane 3 is again consistent with shedding of the gliomedin ectodomain from cell surfaces. Note that a further proteolytic processing product with molecular mass of ϳ45-kDa was also visible in lanes 2 and 3 (Fig. 2B) . Under nonreducing conditions, dimeric forms of the olfactomedin domain were detected (Fig. 2B, lane 1 asterisk) , indicating partial disulfide bonding. Bands corresponding to dimeric (asterisk) forms could also be detected upon analysis of the culture media of cells expressing the full-length protein (Fig. 2B, lane 3) .
N-Glycosylation of Gliomedin-Because gliomedin migrated at a higher electrophoretic mobility than expected and harbors several predicted N-linked glycosylation sites, purified protein was subjected to N-glycosidase F digestion. The result was that recombinant olfactomedin and ectodomain fragments and material purified from media of cells expressing full-length gliomedin all showed clear reductions in apparent molecular mass compared with untreated controls (Fig. 2C) . These results indicate that roughly 25% of the molecular mass of gliomedin is contributed by N-linked glycosylation in HEK-293 cells. In agreement with predictions at the amino acid sequence level (Fig. 1A) , these results also demonstrate that actual N-linked glycosylation sites are concentrated in the C-terminal olfactomedin domain. Migration of recombinant proteins with higher than expected electrophoretic mobilities, even after N-glycosidase digestion, suggests additional posttranslational modifica- (2), and recombinant full-length protein (3) were detected using an anti-His antibody. B, analysis of the same culture media using affinity-purified polyclonal Ab KR 34 under reducing (right) and non-reducing conditions (left). The olfactomedin domain (1) has a molecular mass of ϳ50 kDa, and the ectodomain (2) and full-length protein (3) have molecular masses of ϳ90 kDa. A proteolytic processing product of the ectodomain and full-length protein can be detected at ϳ45 kDa. Under non-reducing conditions (right), putative dimeric forms (asterisks) were also detected, indicating partial interchain disulfide bonding. C, the recombinant expressed and purified olfactomedin domain (1), ectodomain (2), and full-length gliomedin (3) were incubated in the presence or absence of N-glycosidase F (PNGase). Digested and undigested protein were loaded in equal amounts and separated under reducing conditions. The gel was stained with Coomassie Brilliant Blue G250. Molecular mass standards in kDa are shown on the left.
tions, such as glycosylation at predicted O-linked glycosylation sites.
Visualization of Gliomedin-To obtain initial insights into gliomedin structure, the recombinant ectodomain was visualized by transmission electron microscopy after rotary shadowing. Molecules included thin rod-like regions that likely correspond to the more N-terminal portion of trimeric gliomedin in which collagenous domains of three gliomedin molecules intertwine to form a triple helix (Fig. 3, A and B) . Triple helices tend to confer rod-like configurations to proteins. The rod-like portion of gliomedin probably includes parts of linker regions as well as collagenous domains. It is 30 Ϯ 10 nm in length without any conspicuous kinks. At the C terminus of trimeric gliomedin, three globules correspond to the olfactomedin domains. Single globular olfactomedin domains were also detected (Fig.  3, A and B) , perhaps resulting from proteolytic processing.
Gliomedin Is Localized to the Nodes of Ranvier-Localization of gliomedin was investigated using polyclonal antibodies, generated as described above. In contrast to the homologous C. elegans protein Unc-122 (10), gliomedin is not localized at the NMJ (data not shown). Rather, analysis of cross-sections of mouse adult limb muscle via indirect immunofluorescence found gliomedin to be localized along motoneurons in a repetitive pattern (data not shown). Therefore, sciatic nerves of 8-week-old mice were dissected and fixed on coverslips for further immunofluorescence analysis. Using pAb KR 34, specific staining at the nodes of Ranvier was observed (Fig. 4A ). Higher magnification confirmed that gliomedin shows a sharp and distinct expression at the nodal regions of myelinated axons (Fig.  4B ) and in vesicle-like structures of unknown origin. Doublelabeling experiments with antibodies against gliomedin and laminin ␥1 showed overlapping immunoreactivity only at the edge of the nodes (Fig. 4C) , where the Schwann cell basal lamina protects the nodal region. Gliomedin was seen to be restricted to the nodal region, in contrast to the laminin ␥1 subunit, which is also found at the perineurium (connective tissue that bundles several nerve fibers), endoneurium (Schwann cell basal lamina), and the nodes of Ranvier (34) . The nodes are known to be the region for sodium channel clustering that is obligatory for saltatory conduction. Double-labeling with anti-Na ϩ channel antibodies showed immunoreactivity partially overlapped that of gliomedin (Fig. 4D) . However, whereas anti-Na ϩ channel antibodies primarily stained the nodal axoplasma membrane (arrow), staining for gliomedin was also observed around the axon in the area of the nodal gap corresponding to the position of Schwann cell microvilli (Fig. 4D, arrowhead) . Interestingly, analysis of teased fibers of the sciatic nerves of Cgt Ϫ/Ϫ mice (UDP galactosyltransferase 8A), which lack the major lipid components galactocerebrosides and sulfatides in peripheral nervous system and central nervous system myelin, showed the gliomedin-positive areas at Cgt Ϫ/Ϫ nodes to be markedly enlarged compared with wild type nodes (Fig. 5) .
Characterization of Different Gliomedin Forms in Vitro and in Vivo-To address the question of whether gliomedin might be shed and processed in cell lines other than HEK-293, gliomedin expression was analyzed subsequent to transfection of an expression vector for full-length gliomedin into Cos-7 cells, rat glioma cell line C6, and rat schwannoma cell line RN-2. In cell layers extracted with buffer containing Nonidet P-40, a doublet corresponding to full-length gliomedin and cell-associated ectodomain was detected in all cell lines (Fig. 6A) . In culture media a form of gliomedin corresponding in size to shed ectodomain was detected in C6 and RN-2 cells, whereas in Cos-7 cells the ectodomain appeared to be completely processed to a protein fragment corresponding to the C-terminal olfactomedin domain. This latter processing event occurred in the two other cell lines, although to lesser extents (Fig. 6A) . To address the question of whether shedding and processing of gliomedin also occurs in vivo, extracts of sciatic nerves dissected from 8-week-old mice were analyzed. Only use of 6 M urea and 2% Triton X-114 enabled extraction of amounts of full-length gliomedin (Fig. 6B, band 1) and ectodomain (Fig. 6B,  band 2 ) sufficient for detection. Upon analysis of the insoluble Gliomedin is located at the nodes of Ranvier. A, polyclonal antibody KR 34 stains isolated nerve fibers in a repetitive pattern. In a bundle of nerve fibers, gliomedin is located at the nodes of Ranvier. B, localization of gliomedin at a single node of Ranvier at higher magnification. Gliomedin also seems to be present in vesicles close to the node. C, double staining of gliomedin (red) and laminin ␥1 (green) indicate a small overlapping region (arrow). D, double staining of gliomedin (red) and sodium channels (green) also show some overlapping areas along the axon (arrow).
pellet fraction, the olfactomedin-containing fragment was also successfully detected in tissue extracts (Fig. 6B, band 3) . Thus, the three different forms of gliomedin detected in vitro were also detected in vivo (medium of 293 cells overexpressing ectodomain is shown in lane 1 of Fig. 6B ; see Fig. 6B for a comparison of band mobilities). However, extraction of the ectodomain was only possible under denaturing conditions. Interestingly, the ϳ45-kDa processed olfactomedin domain was not extractable from sciatic nerve tissue at all.
The identity of the ectodomain band in tissue extracts was further verified by digestion with highly purified bacterial collagenase. Gliomedin is the only vertebrate protein comprising both collagenous and olfactomedin domains. Because pAb KR 34 was raised against the olfactomedin domain, a collagenase-digestible protein band detectable by pAb KR 34 must correspond to gliomedin. As can be seen, collagenase digestion reduced both full-length and ectodomain forms in urea extracts (Fig. 6C, doublet 1) to a resistant fragment of 45 kDa, corresponding to the olfactomedin domain (Fig. 6C, band 2) . Therefore, gliomedin is identified as an authentic component of sciatic nerve tissue in the peripheral nervous system. Interestingly, a collagenase-sensitive protein band visualized with pAb KR 34 was also extractable from brain tissue (data not shown).
Rapid Turnover of Cell Surfacebiotinylated Gliomedin-Turnover of gliomedin at the cell surface was followed using HEK-293 cells stably expressing full-length gliomedin. Toward this end cells were surfacebiotinylated and analyzed over time. As can be seen, biotinylated gliomedin was readily detected for up to 16 h in cell extracts (Fig. 7) .
Gliomedin Is Shed in a Furin-dependent Manner and Is Further Processed by a Metalloprotease-To
gain further insights into gliomedin processing, the identities of responsible proteases were investigated. Stably transfected HEK-293 cells were cultured in the presence of different protease inhibitors, and inhibition of ectodomain shedding from the cell surface was characterized (Fig. 8A) . Additionally, stably transfected Cos-7 cells were incubated in the presence of inhibitors to study processing of the olfactomedin domain (Fig. 8B ), since this cell line possesses the capacity to process the latter to completion (Fig. 6A) . Shedding of the ectodomain from the cell surface was not affected using different concentrations of AEBSF, E-64, pepstatin A, and the metalloprotease inhibitor o-phenanthroline. However, ϳ50% inhibition was observed in the presence of furin inhibitor decRVKRcmk (Fig. 8A) . Densitometric quantification of HEK-293 cells treated with aprotinin or furin inhibitor decRVKRcmk confirmed the specificity of furin-dependent shedding, since the former (a serine protease inhibitor) had no effect, whereas the latter resulted in marked inhibition of ectodomain shedding (Fig. 8A, lower panel) . In regard to olfactomedin domain processing, no significant inhibition was detected using AEBSF, E-64, pepstatin A, or the hydroxamate inhibitor BB 3103. Furin inhibitor decRVKRcmk nodes (D-F) were about twice the size of areas associated with wt nodes (A-C). The nodal area was quantified using ImageJ software (freeware, NIH). Axons were divided into three groups according to their diameters. In each single group the nodal area is significantly larger (G; *, p Ͻ 0.03; **, p Ͻ 0,003; ***, p Ͻ 0.0003; Student's t test). In addition, the ratio of node area to the axon diameter is also significantly enhanced in the Cgt Ϫ/Ϫ mice (H; p Ͻ 0.0001; Student's t test). Bars represent 20 m.
showed a slight inhibition in olfactomedin domain processing, likely due to the fact that the amount of ectodomain is reduced. In contrast, a 33% reduction in processing could be observed using the metalloprotease inhibitor o-phenanthroline (Fig. 8B) .
Inhibition of this processing by o-phenanthroline was confirmed by immunoblot analysis, in which densitometric quantification of Cos-7 cells treated with hydroxamate inhibitor BB 3103 or o-phenanthroline showed inhibition of olfactomedin domain processing only by the latter (Fig. 8B, lower panel) . Processing of the gliomedin olfactomedin domain is, therefore, dependent upon a metalloprotease.
Use of Defined Cleavage Sites in Gliomedin-To ascertain the cleavage sites used for ectodomain shedding and olfactomedin domain processing, purified protein fragments were subjected to N-terminal amino acid sequencing. The N-terminal sequence of purified ectodomain was 95 SHNGE 99 , which occurs immediately downstream of the putative furin recognition site 91 RNKR 94 (Fig. 9A) . Two additional N-terminal sequences from minor products resulting from cleavages just upstream of the collagenous domain were also obtained (
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126 and 124 VMIDL 128 ; Fig. 9A ). The N-terminal sequence of the 45-kDa gliomedin domain-containing fragment was found to be 278 DDTLV 282 (Fig. 9A) , which suggested that cleavage at this site might result from processing by BMP-1/Tolloid-related proteinases, which often cleave at sites with Asp residues in P1Ј positions (30) .
To further validate conclusions regarding the possible identities of responsible proteinases, site-directed mutagenesis of the putative cleavage sites was performed. To destroy the putative furin cleavage site, (Fig. 9B) ; the R91A mutation resulted in greatly decreased amounts of ectodomain, and the D278A/D279A mutation resulted in greatly decreased amounts of olfactomedin domain in conditioned media. In addition, the mutations led to increased amounts of uncleaved protein associated with cell surfaces (Fig. 9B,  lower panel) . Results similar to the above were observed upon transfection of mutant constructs into the schwannoma cell line RN-2 (data not shown).
Gliomedin Is a Substrate for BMP-1-To directly address the question of whether BMP-1 can cleave the olfactomedin domain from gliomedin, gliomedin ectodomain was incubated in the presence or absence of BMP-1 in an in vitro cleavage assay. As can be seen (Fig. 10A) , in addition to the 75-kDa ectodomain, the starting material already contained some cleaved material due to co-purification of C-terminal-tagged ectodomain and C-terminal-tagged processed olfactomedin domain from conditioned media. In addition, aggregates A, Cos-7, C6 (glioma), and RN-2 (schwannoma) cells were transfected with a full-length gliomedin expression construct. Cell extracts and media were separated under reducing conditions and detected by immunoblotting with pAb KR 34. In all cell extracts (C) a double band can be detected corresponding to full-length gliomedin and a shed form attached to the cell layer. In media (M) a soluble ectodomain can only be detected in C6 and RN-2 cells, whereas another processing product corresponding to the olfactomedin domain can be detected with different intensities in all cell lines. B, mouse sciatic nerves were extracted with Triton X-114 and 6 M urea and separated under reducing conditions using on a 6 M urea gel (4 -12%). Medium of transfected HEK-293 cells was used for comparison. After immunoblotting, full-length gliomedin (1) and the ectodomain (2) were visualized with pAb KR 34. Analyzing the insoluble pellet, a shorter form corresponding to the olfactomedin domain (3) could also be seen. C, the 80-kDa band was sensitive to collagenase treatment, and a remaining 40-kDa fragment corresponding to the olfactomedin domain could be detected. Molecular mass standards in kDa are shown on the left. greater than 250 kDa were detected in the starting material by pAb KR 34, which recognizes the olfactomedin domain. Although incubation of the sample alone for 18 h at 37°C did not markedly change the pattern of bands, incubation in the presence of BMP-1 resulted in the disappearance of intact ectodomain with an increase in the amount of high molecular weight aggregate (Fig. 10A, asterisk) . Because bands were detected with pAb KR 34, which recognizes the oflfactomedin domain, results were consistent with the interpretation that olfactomedin domains cleaved from ectodomains by BMP-1 participated in the formation of the high molecular weight aggregates. To more clearly ascertain the role of BMP-1 in processing gliomedin, N-tagged ectodomain was prepared to avoid the presence of co-purified cleaved olfactomedin domain in starting material, and in vitro cleavage assays were performed in the presence of Brij 35 to prevent formation of aggregates. Using these new conditions (Fig. 10B) , results clearly show that BMP-1 processes the glomedin ectodomain to produce an ϳ45-kDa olfactomedin cleavage product. Importantly, N-terminal sequencing showed the ϳ45-kDa fragment produced by in vitro processing of ectodomain by BMP-1 to have the same 278 
DDTLV
282 N terminus as the ϳ45-kDa olfactomedin domain-containing fragment produced by processing of gliomedin by cells. Consistent with the conclusion that cells employ BMP-1-like metalloproteinases to cleave the olfactomedin domain from gliomedin, culturing of HEK-293 cells expressing ectodomain in the presence of FG2575, a specific inhibitor of the BMP-1/Tolloid-like proteinases, inhibited possessing of the gliomedin ectodomain to produce the ϳ45-kDa olfactomedin domain fragment (Fig. 10C) . N-terminal sequencing of the high molecular mass aggregates seen in Fig.  10A produced the sequence 278 DDTLV 282 , consistent with the conclusion that cleaved olfactomedin domains aggregate into higher order forms.
DISCUSSION
Gliomedin belongs to the new protein family of colmedins (10) and exhibits a unique domain structure among proteins in vertebrates, with its combination of type II transmembrane-, collagenous-, and olfactomedin-like domains. Our data show that gliomedin is a highly N-glycosylated, trimeric molecule localized at the nodes of Ranvier. The N-glycosylation sites are located within the olfactomedin domain, as shown for other olfactomedin domain-containing proteins like Noelin and Amassin (13, 14) . Gliomedin possesses a single juxtamembrane coiled-coil motif of 14 amino acids, suggesting an ␣-helical domain that might serve as a nucleus for N-to C-terminalinduced trimerization of the ␣-chains, as shown for collagen XIII (35, 36) . However, in contrast to other transmembrane collagens, gliomedin lacks a second coiled-coil domain at the C terminus of the protein. The assumed trimeric structure for the gliomedin ectodomain was confirmed by electron microscopy. The latter identified an ϳ30-nm rod-like structure that likely corresponds to a triple helix formed by the 108-amino acid collagenous domain, which is predicted to form a 31.2-nm triple helix. In addition, three globular C-terminal domains were observed, and these likely correspond to the olfactomedin domains of the trimeric protein. Thus far, no structural information is available for the latter protein domain, although secondary structure predictions and circular dichroism measurements suggest an all ␤-structure for the highly conserved olfactomedin domain in myocilin (37, 38) and amassin (39) .
Collagen trimers are many times stabilized via interchain disulfide bonds. However, recombinant full-length gliomedin and ectodomain secreted into culture medium are seen on nonreducing gels to be incompletely cross-linked by disulfide bridges. Such partial disulfide formation has been previously observed for other recombinant collagens (40) . The two collagenous regions of gliomedin contain no cysteine residues but are flanked by two pairs of cysteines, 129 CNSTQGIC 136 and 268 CPGETC 273 . Some or all of these cysteines may be involved in intermolecular disulfide bonding that enhances stability of endogenous trimeric gliomedin molecules. Another cysteine residue is found directly adjacent to the plasma membrane, and a sixth cysteine located within the olfactomedin domain might mediate aggregation via intermolecular disulfide bonding.
UNC-122, a putative orthologue of gliomedin in C. elegans, is localized to the NMJ. In contrast, vertebrate gliomedin is expressed solely at the nodes of Ranvier. In fact, immunofluorescent analysis of teased adult mouse sciatic nerve suggests that gliomedin is expressed only at the node margins, where the Schwann cell basal lamina protects the nodal region. Eshed et al. (23) , who independently discovered gliomedin while work described in the present report was in progress, have recently shown gliomedin to localize to Schwann cell microvilli in close contact with the nodes of Ranvier (23) . The latter findings complement those presented here and confirm the specificity of the purified polyclonal antibodies used in the present study. In the present study staining of sciatic nerves from Cgt Ϫ/Ϫ mice, a disease model in which the UDP galactosyltransferase 8A gene is disrupted, showed the domain for gliomedin staining around the nodes of Ranvier to be almost doubled. Thus, whereas gliomedin deposition has been shown to be necessary to proper node formation (23) , it is demonstrated here that appropriate gliomedin deposition is itself dependent upon proper peripheral nerve myelinization, as Cgt is essential to biosynthesis of the two major myelin galactolipids.
Full-length, membrane-bound gliomedin is rapidly shed from the surfaces of cultured cells. In addition, the ectodomain can be further processed with release of the olfactomedin-containing domain from the collagenous domain, as evidenced by the appearance of free olfactomedin domains in immunoblots and as globular particles in electron micrographs. These cleavage processes are not mere cell culture artifacts but also occur in tissues, as full-length gliomedin, ectodomain, and olfactomedin domains were all found as authentic components of sciatic nerves. Here we have demonstrated that furin-like proprotein convertases are directly involved in gliomedin ectodomain shedding via cleavage at an RNKR consensus sequence. Furthermore, we have demonstrated gliomedin to be a substrate for BMP-1/Tolloid-like metalloproteinases, which mediate release of the C-terminal olfactomedin domain both in vitro and in cell culture systems.
The tissue forms of gliomedin were identified by immunoblotting of mouse sciatic nerve and brain extracts. Polyclonal antibody KR 34 recognized two predominant protein bands at ϳ90 and ϳ85 kDa, corresponding in size to full-length gliomedin and ectodomain, respectively. Gliomedin seems to be involved in strong protein-protein interactions, since it can only be extracted from sciatic nerve under strong denaturing conditions. Interestingly, cleaved olfactomedin domain was detectable only in the insoluble pellet fraction of neural tissues. This suggests that the olfactomedin domain, once cleaved from full-length gliomedin and/or the ectodomain, is incorporated as an integral part of nerve-associated matrix. Thus, gliomedin is shed from cell surfaces in vitro and in vivo and undergoes further processing.
Overexpressing full-length gliomedin in different cell lines first led to the observation that gliomedin exists in two different forms; a transmembrane protein and a soluble, released ectodomain. Interestingly, a double band was obtained in cell extracts of all cell lines analyzed thus far, with the lower band corresponding in size to the ectodomain observed in media. Presumably, ectodomain in cell extracts is derived from gliomedin molecules still anchored in the cell membrane because one or two of the three chains remains uncleaved by furin. Pulse-chase experiments on cells expressing membrane-bound gliomedin revealed rapid shedding of the protein from cell surfaces as shown for collagens XVII and XIII (3, 41) .
Here we have shown that the furin family is solely responsible for gliomedin shedding, since release of the ectodomain was blocked by decRVKRcmk, a specific inhibitor of this group (42), and not by inhibitors of other protease families. Furthermore, N-terminal sequencing of purified ectodomain demonstrated that cleavage had indeed occurred C-terminal to the RNKR consensus sequence, whereas substituting alanine for the first arginine of the consensus sequence resulted in a dramatic decline in ectodomain shedding.
It should be noted that none of the gliomedin forms shorter than the full-length protein is likely due to alternative splicing, since only a single mRNA transcript of about 6 kilobases for gliomedin has been detected (23) .
Additional processing of the gliomedin ectodomain, resulting in release of the olfactomedin domain, was reduced in the presence of o-phenanthroline, thus showing the process to be metalloprotease-dependent. N-terminal sequencing of cleaved olfactomedin domain-containing fragments and their oligomers indicated the use of a 275 IPN2DDT 280 cleavage site in the linker region between the collagenous and olfactomedin domains. This conclusion was confirmed by site-directed mutagenesis. This site resembles in a number of respects cleavage sites employed by the BMP-1/Tolloid-like metalloproteinases in the majority of their known substrates (30) . In addition, in vitro cleavage assays confirmed that such proteinases cleave gliomedin at the predicted site. Moreover, studies with FG2575, a specific inhibitor of BMP-1/Tolloid-like proteinases, revealed that cleavage of the gliomedin olfactomedin domain in cell cultures indeed appears to be mediated by such proteinases. Thus, processing of gliomedin by BMP-1/Tolloid-like proteinases releases olfactomedin domains. Other evidence presented herein suggests that this cleavage event facilitates formation of stable oligomers that may subserve some portion of gliomedin function. There is evidence for physiological processing of other molecules that contain olfactomedin domains. For example, myocilin was recently shown to be cleaved endoproteolytically in the linker region between the N-terminal and olfactomedin domains (43) . However, details concerning the processing of other olfactomedin domain-containing proteins and what differences or similarities that such processing may have to the processing of gliomedin described here remain to be characterized. Importantly, shedding by furin of type II-oriented molecules with collagenous domains can be of key importance to their biological functions, as demonstrated for ectodysplasin A. In the latter case, 20% of disease-causing mutations found in the human gene for ectodysplasin A are mutations located within the furin consensus sequence, rendering this site resistant to cleavage (5) .
In all of the sequenced or predicted orthologous genes of gliomedin across species, a furin consensus sequence is conserved close to the N-terminal region. In addition, experimental evidence indicates that the ectodomain of UNC-122, the homologous colmedin in C. elegans, is indeed shed (10) . BMP-1/Tolloid-like proteinases have previously been shown to cleave almost exclusively at scissile bonds with an aspartate in the P1Ј position (30) . In fact, many previously described substrates of these proteinases (including the precursor forms of collagen types I and III, lysyl oxidase, laminin 5, dentin matrix protein 1, biglycan, osteoglcin, and myostatin) also have an aspartate or glutamate in the P2Ј position that may facilitate processing (30) . The gliomedin BMP-1 cleavage site contains aspartates in both the P1Ј and P2Ј positions, and interestingly, this arrangement is conserved in all gliomedins across mammalian species. It is also conserved in chick and in the homologous colmedins of C. elegans and D. melanogaster in which putative BMP-1 cleavage sites with two conserved aspartate residues are found juxtaposed to the olfactomedin domains. In Danio rerio and Tetraodon nigroviridis a putative cleavage site for BMP-1/ Tolloid-like proteinases can be identified in a similar position in gliomedin. Thus, cleavage of olfactomedin domains by BMP-1/ Tolloid-like proteinases may be essential to the overall functions of colmedins in a broad range of species.
Rescue experiments with the C. elegans gliomedin homologue UNC-122 indicate that the olfactomedin domain is needed for proper NMJ signaling, as mutant proteins with deletion of any domain except the olfactomedin domain were able to rescue mutant unc-122 locomotory defects (10) . Similarly, were further analyzed in Cos-7 cells. Culture media were treated as described above. Samples were analyzed in triplicate. *, inhibition was not densitometrically analyzed.
the gliomedin olfactomedin domain has been shown to be sufficient for inducing formation of the nodes of Ranvier in a cell culture model (23) . Before the Na ϩ channel clustering that characterizes node formation, axonal cell adhesion molecules NrCAM and neurofascin 186 must be clustered (44) , and this event appears to be triggered by binding of gliomedin to these FIGURE 9. Use of defined cleavage sites in gliomedin. A, Edman degradation was performed to determine the N-terminal sequences of purified protein fragments, and the different N-terminal sequences are shown. In addition to the furin-cleaved fragment, low abundance products cleaved 28 and 30 amino acids downstream of the furin site were also observed. Sequencing of the olfactomedin domain revealed a putative BMP-1 cleavage site starting at amino acid 278. B, site-directed mutagenesis of full-length gliomedin was performed to generate 91A and D278A/D279A mutations. The mutant constructs were transiently transfected into HEK-293 cells. Equal amounts of cultured media of mutant and control cells were analyzed by SDS-PAGE, and the immunoblots were stained with pAb KR 34. Molecular mass standards in kDa are shown on the left. The histogram depicts densitometric measurements (n ϭ 3) of immunoblot signals, with the distributions of cell-associated gliomedin, shed ectodomain, and processed olfactomedin domain compared between mutant and wild type gliomedin-expressing control cells. A, BMP-1 cleavage assays were performed with C-terminal-tagged, co-purified ectodomain and olfactomedin domain. Starting material (SM) and samples incubated in the presence or absence of BMP-1 were analyzed by immunoblotting with pAb KR 34. Note that there are already aggregates in the starting material which increase after incubation with BMP-1 (asterisk). B, the same assay was performed with N-terminaltagged ectodomain. Note that only ectodomain is present in the starting material. To overcome aggregates, 0.01% Brij 35 was added to the assay. Immunoblotting was accomplished using pAb KR 34. C, HEK-293 cells were cultured in the presence/absence of 20 M FG 2575, a specific inhibitor of BMP-1/Tolloid-like proteinases. Defined amounts of precipitated media were separated on a 10% SDS-PAGE gel, and immunoblotting was accomplished using pAb KR 34. All gels were run under reduced conditions, and molecular mass standards in kDa are shown on the left.
receptors (23, 45) . It is interesting to speculate that during development shed gliomedin ectodomain may function as a diffusible factor to initiate node formation. That gliomedin is capable of initiating axonal node formation in the absence of glial cells is supported by the observation that an exogenously added olfactomedin domain-Fc fusion protein is sufficient to induce nodal-like clustering of Na ϩ -channels and associated scaffolding proteins in axons (23) . In a later event, unshed gliomedin may be necessary for establishing direct contact between the tips of Schwann cell microvilli and the nodal axolemma. Subsequently, in a third event olfactomedin domains released by BMP-1/Tolloid-like proteinases may form insoluble aggregates that act to stabilize mature nodes of Ranvier. Olfactomedin domains tend to form aggregates, and these oligomerizations constitute an important component of olfactomedin domain function, as previously inferred for olfactomedin domain-containing proteins myocilin (46) and amassin (13) . Future experiments are needed to further elucidate the roles of the different proteolysis-generated forms of gliomedin in the induction and maintenance of the nodes of Ranvier.
